Latest On Evotec SE (EVOTF):
| Date/Time | Type | Description | Signal | Details |
|---|---|---|---|---|
| 2023-05-10 10:48 EST | News | Novartis' Sandoz to use Evotec's technology in pact to develop biosimilars | N/A |  |
| 2023-03-28 16:16 EST | News | Evotec SE (EVOTF) Q4 2022 Earnings Call Transcript | N/A | |
| 2023-03-24 20:43 EST | News | Evotec gets $6.6M from Gates Foundation to develop short-regimen TB drugs | N/A | |
| 2022-12-16 15:05 EST | News | Evotec to get $26M from Bristol Myers as drug projects added under neuroscience pact | N/A | |
| 2022-12-15 03:27 EST | News | Evotec SE: Profitable, Innovative, And The Omics Opportunity | N/A | |
| 2022-11-12 16:10 EST | News | Evotec SE (EVOTF) Q3 2022 Earnings Call Transcript | N/A | |
| 2022-11-09 17:43 EST | News | Evotec SE reports 9M results; outlook for FY2022 unchanged and mid-term targets 2025 confirmed | N/A | |
| 2022-10-25 20:32 EST | News | Evotec gains on deal to understand autoimmune diseases | N/A | |
| 2022-09-21 19:16 EST | News | Evotec, Adapsyn team up for bioactive small molecules | N/A | |
| 2022-09-20 09:48 EST | News | Evotec stock dips despite US DoD contract up to $49.9M to develop antibody for plague | N/A | |
| 2022-08-25 06:33 EST | News | Evotec to acquire Central Glass Germany to bolster drug substance manufacturing | N/A | |
| 2022-08-13 22:12 EST | News | Evotec SE 2022 Q2 - Results - Earnings Call Presentation | N/A | |
| 2022-08-13 22:12 EST | News | Evotec SE's (EVOTF) CEO Dr. Werner Lanthaler on Q2 2022 Results - Earnings Call Transcript | N/A | |
| 2022-08-11 20:29 EST | News | Evotec SE reports 1H results; updates FY22 guidance and mid-term targets of 2025 confirmed | N/A | |
| 2022-07-06 16:02 EST | News | Boehringer, Evotec, bioMérieux form joint venture Aurobac to combat antimicrobial resistance | N/A | |
| 2022-06-14 10:02 EST | News | J&J, Evotec team up to discover novel therapies | N/A | |
| 2022-05-19 14:08 EST | News | Evotec, Almirall team up to discover therapies for skin diseases | N/A | |
| 2022-05-11 16:09 EST | News | Evotec SE (EVOTF) CEO Werner Lanthaler on Q1 2022 Results - Earnings Call Transcript | N/A | |
| 2022-04-12 06:06 EST | News | Evotec SE reports FY results | N/A | |
| 2022-04-08 09:18 EST | News | Evotec to get $16M from Bristol Myers under ongoing neuroscience collaboration | N/A | |
| 2021-11-17 09:05 EST | News | Evotec SE 2021 Q3 - Results - Earnings Call Presentation | N/A | |
| 2021-11-11 18:31 EST | News | Evotec SE (EVOTF) CEO Werner Lanthaler on Q3 2021 Results - Earnings Call Transcript | N/A | |
| 2021-10-11 22:32 EST | News | Evotec files with SEC for proposed offering of ADS in U.S. | N/A | |
| 2021-09-02 11:52 EST | News | Bristol Myers exercises option for Evotec's EVT8683 in neurodegenerative diseases | N/A | |
| 2021-05-04 11:30 EST | News | Evotec forms alliance to build molecular patient database | N/A | |
| 2021-04-19 22:27 EST | News | Evotec teams up with Kazia Therapeutics for development of EVT801 | N/A | |
| 2021-03-25 06:29 EST | News | Evotec SE reports FY 2020 results | N/A | |
| 2021-03-22 19:48 EST | News | Evotec, Takeda form strategic RNA targeting alliance | N/A | |
| 2020-12-09 11:23 EST | News | Evotec, Sartorius inks partnership for therapeutic exosomes-based startup | N/A | |
| 2020-12-04 18:11 EST | Financials | Company financials have been released. | Neutral | |
| 2020-11-26 23:33 EST | Financials | Company financials have been released. | Neutral | |
| 2020-11-14 14:21 EST | Financials | Company financials have been released. | Neutral | |
| 2020-11-12 12:56 EST | News | Evotec SE reports 9M results | N/A | |
| 2020-11-08 02:29 EST | Financials | Company financials have been released. | Neutral | |
| 2020-11-07 18:50 EST | Financials | Company financials have been released. | Neutral | |
| 2020-10-08 11:43 EST | News | Evotec earns $6M milestone from BMY under neurodegeneration collaboration | N/A | |
| 2020-09-26 15:41 EST | Financials | Company financials have been released. | Neutral | |
| 2020-09-17 08:04 EST | Financials | Company financials have been released. | Neutral | |
| 2020-08-19 02:24 EST | News | Novo teams up with Evotec in kidney diseases | N/A | |
| 2020-08-14 11:45 EST | Financials | Company financials have been released. | Neutral | |
| 2020-08-12 05:41 EST | News | Evotec SE reports 1H results | N/A | |
| 2020-08-06 15:23 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-30 19:32 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-30 07:30 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-29 23:45 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-28 17:16 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-27 15:22 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-23 20:12 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-22 10:14 EST | News | Evotec unit nabs $18.2M grant to develop antibodies against COVID-19 | N/A | |
| 2020-07-21 06:28 EST | News | Evotec partners with Quantro Therapeutics | N/A | |
About Evotec SE (EVOTF):
Evotec SE provides drug discovery and development solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and not-for-profit organizations worldwide. The company's EVT Execute segment offers drug discovery services, such as target identification and validation, hit identification, sample management, chemistry, drug metabolism and pharmacokinetics, research informatics proteomics and metabolomics, bio-reagents, in vitro biology, in vivo pharmacology, biomarkers, and antibody platform; INDiGO, a program for accelerating the early drug candidates into the clinic stage; integrated chemistry, manufacturing, and control services; and integrated drug discovery services. Its EVT Innovate segment is involved in investing and developing early-stage discovery programs, as well as advanced drug candidates in the areas of diabetes and diabetic complications, inflammatory diseases, neuroscience, oncology, and pain and anti-infective. Evotec SE has a strategic drug discovery and development partnership with Celgene Corporation and Related Sciences; strategic research alliance with Novo Nordisk A/S and Celmatix Inc.; collaboration with Sanofi and Almirall; research alliance with Ferring Pharmaceuticals; strategic collaboration with Centogene and Immuneering; drug discovery alliance with LEO Pharma; strategic partnerships with the Sensyne Health plc, Oxford University Innovation Ltd., Secarna Pharmaceuticals GmbH & Co. KG, and Oxford Sciences Innovation to fund LAB10x; and drug discovery and development partnership with Aeovian Pharmaceuticals Inc. The company also has a collaboration with Indivumed GmbH; a partnership with Celmatix Inc.; strategic collaborations with Ildong Pharmaceutical Co., Ltd. and Chinook Therapeutics, Inc.; a drug discovery research collaboration with HitGen Inc.; a partnership with Rappta Therapeutics; and a partnership with Sartorius. The company was founded in 1993 and is headquartered in Hamburg, Germany.
General
- Name Evotec SE
- Symbol EVOTF
- Type Common Stock
- Exchange PINK
- Currency USD
- Country USA
- SectorHealthcare
- IndustryDrug Manufacturers-Specialty & Generic
- Full Time Employees 3,444
- Fiscal Year EndDecember
- Web URLhttp://www.evotec.com
Valuation
- Trailing PE 274.11
- Forward PE 147.06
- Price/Sales (Trailing 12 Mt.) 8.91
- Price/Book (Most Recent Quarter) 9.91
- Enterprise Value Revenue 12.38
- Enterprise Value EBITDA 146.76
Financials
- Most Recent Quarter 2020-09-30
- Profit Margin 3%
- Return on Assets 3%
- Return on Equity 3%
- Revenue Per Share $0
- Gross Profit 132.89 million
- Quarterly Earnings Growth 13.3%
Highlights
- Market Capitalization 5.74 billion
Share Statistics
- Shares Outstanding 163.49 million
- Shares Float 115.83 million
- % Held by Insiders 1476%
- % Held by Institutions 69.92%
Technicals
- Beta 0.81
- 52 Week High $43.3
- 52 Week Low $20.5
- 50 Day Moving Average 39.42
- 200 Day Moving Average 32.31
Dividends
- Dividend Date N/A
- ExDividend Date N/A
- Dividend Yield 0%
Evotec SE (EVOTF) Dividend Calendar:
| Ex-Dividend Date | Payment Date | Record Date | Declared Date | Amount |
|---|
Evotec SE (EVOTF) Earnings History:
Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.
| Quarter Date | Report Date | Actual Revenue | Reported EPS | EPS Estimate | Deviation from Estimate |
|---|---|---|---|---|---|
| 2020-09-30 | 2020-09-30 | $N/A | -$0.01 | ||
| 2020-06-30 | 2020-09-30 | $N/A | -$0.01 | $0.01 | -209% |
| 2020-03-31 | 2020-06-30 | $119.4 million | -$0.07 | $0.06 | -221.67% |
| 2019-12-31 | 2020-03-31 | $125.08 million | $0.12 | $0.04 | 203% |
| 2019-09-30 | 2019-12-31 | $114.27 million | $0.06 | $0.08 | -27.38% |
| 2019-06-30 | 2019-09-30 | $103.24 million | $0.14 | $0.11 | 26% |
| 2019-03-31 | 2019-06-30 | $103.85 million | -$0.02 | $0.08 | -122.75% |
| 2018-12-31 | 2019-03-31 | $105.39 million | $0.10 | $0.06 | 63.67% |
| 2018-09-30 | 2018-12-31 | $96.26 million | $0.23 | $0.04 | 473% |
| 2018-06-30 | 2018-09-30 | $94.77 million | $0.27 | $0.05 | 434% |
| 2018-03-31 | 2018-06-30 | $78.98 million | $0.11 | $0.02 | 466.5% |
| 2017-12-31 | 2018-03-31 | $86.78 million | $0.02 | ||
| 2017-09-30 | 2017-12-31 | $67.46 million | $0.08 | $0.04 | 101.5% |
| 2017-06-30 | 2017-09-30 | $53.21 million | $0.02 | $0.04 | -52% |
| 2017-03-31 | 2017-06-30 | $50.18 million | $0.02 | $0.04 | -43% |
| 2016-12-31 | 2017-03-31 | $43.88 million | $0.05 | -$0.02 | 366.5% |
| 2016-09-30 | 2016-12-31 | $0.11 | $0.01 | 1038% | |
| 2016-06-30 | 2016-09-30 | $0.07 | |||
| 2016-03-31 | 2016-06-30 | $0.03 | -$0.01 | 433% | |
| 2015-12-31 | 2016-03-31 | -$0.01 | $0.01 | -214% | |
| 2015-09-30 | 2015-12-31 | $0.04 | |||
| 2015-06-30 | 2015-09-30 | -$0.02 | $0.01 | -345% | |
| 2015-03-31 | 2015-06-30 | $0.12 | |||
| 2014-12-31 | 2015-03-31 | -$0.01 | -$0.01 | 12% | |
| 2014-09-30 | 2014-12-31 | $0.01 | -$0.06 | 115.67% | |
| 2014-06-30 | 2014-09-30 | -$0.04 | |||
| 2014-03-31 | 2014-06-30 | $-0.00 | |||
| 2013-12-31 | 2014-03-31 | -$0.04 | |||
| 2013-09-30 | 2013-12-31 | -$0.22 | |||
| 2013-06-30 | 2013-09-30 | $-0.00 | |||
| 2013-03-31 | 2013-06-30 | -$0.02 | |||
| 2012-12-31 | 2013-03-31 | -$0.03 | |||
| 2012-09-30 | 2012-12-31 | -$0.06 | |||
| 2012-06-30 | 2012-09-30 | $0.06 | |||
| 2012-03-31 | 2012-06-30 | $0.04 | |||
| 2011-12-31 | 2012-03-31 | -$0.02 | |||
| 2011-09-30 | 2011-12-31 | -$0.03 | |||
| 2011-06-30 | 2011-09-30 | $0.09 | |||
| 2011-03-31 | 2011-06-30 | $0.01 | |||
| 2010-12-31 | 2011-03-31 | $-0.00 | |||
| 2010-09-30 | 2010-12-31 | $0.03 | |||
| 2010-06-30 | 2010-06-30 | $0.01 | |||
| 2010-03-31 | 2010-03-31 | -$0.02 | |||
| 2009-12-31 | 2009-12-31 | -$0.16 | |||
| 2009-09-30 | 2009-09-30 | -$0.05 | |||
| 2009-06-30 | 2009-06-30 | -$0.11 | |||
| 2009-03-31 | 2009-03-31 | -$0.27 | |||
| 2008-12-31 | 2008-12-31 | -$0.68 | |||
| 2008-09-30 | 2008-09-30 | -$0.04 | |||
| 2008-06-30 | 2008-06-30 | -$0.20 | |||
| 2008-03-31 | 2008-03-31 | -$0.28 | |||
| 2007-03-31 | 2007-03-31 | $0.05 | |||
| 2006-12-31 | 2006-12-31 | -$0.32 | |||
| 2006-09-30 | 2006-09-30 | -$0.09 | |||
| 2006-06-30 | 2006-06-30 | -$0.02 | |||
| 2006-03-31 | 2006-03-31 | -$0.20 |
Evotec SE (EVOTF) Company Financial Statements:
Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.
Income Statement:
| Date | Sep 30 2020 | Jun 30 2020 | Mar 31 2020 | Dec 31 2019 | Sep 30 2019 |
|---|---|---|---|---|---|
| Research Development | N/A | N/A | 15.06 million | 17.15 million | 12 million |
| Income Before Tax | N/A | N/A | 18.87 million | 12.82 million | 24.8 million |
| Selling General Administrative | N/A | N/A | 17.25 million | 19.53 million | 16.33 million |
| Gross Profit | N/A | N/A | 33.27 million | 34.08 million | 35.01 million |
| Ebit | N/A | N/A | 21.62 million | 16.92 million | 22.39 million |
| Operating Income | N/A | N/A | 16.1 million | 16.92 million | 22.39 million |
| Income Tax Expense | 8.93 million | 2.77 million | N/A | 5.3 million | 5.75 million |
| Total Revenue | N/A | N/A | 119.4 million | 125.08 million | 114.27 million |
| Cost of Revenue | N/A | N/A | 86.13 million | 90.99 million | 79.27 million |
| Total Other Income Expense Net | N/A | N/A | N/A | -4.1 million | 2.41 million |
| Net Income From Continuing Operations | N/A | N/A | 17.08 million | 7.52 million | 19.05 million |
| Net Income Applicable to Common Shares | -1.41 million | -9.82 million | N/A | 8.36 million | 19.05 million |
Cash Flow:
| Date | Sep 30 2020 | Jun 30 2020 | Mar 31 2020 | Dec 31 2019 | Sep 30 2019 |
|---|---|---|---|---|---|
| Investments | N/A | N/A | -13.51 million | -16.75 million | -57.27 million |
| Change to Liabilities | N/A | N/A | N/A | -16.71 million | N/A |
| Total Cash Flow from Investing Activities | -29.7 million | -39.64 million | N/A | -28 million | -64.02 million |
| Net Borrowings | -3.11 million | 11.3 million | N/A | 13.69 million | -22.79 million |
| Total Cash Flow from Financial Activities | N/A | N/A | N/A | 14.07 million | -22.15 million |
| Change to Operating Activities | 6.62 million | -44.39 million | N/A | 54.68 million | -22.57 million |
| Change in Cash | N/A | N/A | 10.02 million | 27.42 million | -72.64 million |
| Total Cash from Operating Activities | 27.76 million | -34.1 million | 27.13 million | 40.98 million | 12.21 million |
| Depreciation | N/A | N/A | N/A | 12.22 million | 12.65 million |
| Other Cash Flow from Investing Activities | N/A | N/A | N/A | N/A | N/A |
| Change to Inventory | N/A | N/A | N/A | -1.36 million | N/A |
| Change to Account Receivables | N/A | N/A | N/A | -32.48 million | N/A |
| Other Cash Flow from Financing Activities | N/A | N/A | N/A | N/A | N/A |
| Change to Net Income | 50.9 million | -8.25 million | N/A | 2.24 million | 3.08 million |
| Capital Expenditures | N/A | N/A | 16.34 million | 10.96 million | 5.95 million |
Balance Sheet:
| Date | Sep 30 2020 | Jun 30 2020 | Mar 31 2020 | Dec 31 2019 | Sep 30 2019 |
|---|---|---|---|---|---|
| Total Liabailities | N/A | N/A | 694.09 million | 703.88 million | 621.29 million |
| Total Stockholder Equity | N/A | N/A | 489.47 million | 477.03 million | 461.79 million |
| Other Current Liabilities | 121.81 million | N/A | 9.86 million | 96 million | 90.19 million |
| Total Assets | N/A | N/A | 1.18 billion | 1.18 billion | 1.08 billion |
| Common Stock | 151.9 million | 151.45 million | N/A | 150.9 million | 150.53 million |
| Other Current Assets | N/A | N/A | N/A | 10.11 million | N/A |
| Retained Earnings | -435.4 million | -433.88 million | -429.2 million | -441.18 million | -449.08 million |
| Other Liabilities | 76.29 million | 66.89 million | N/A | 82.56 million | 64.6 million |
| Other Assets | 66.46 million | 68.76 million | N/A | 57.99 million | 56.29 million |
| Cash | N/A | N/A | 285.41 million | 277.03 million | 249.62 million |
| Total Current Liabilities | 194.88 million | N/A | 185.04 million | 178.96 million | 133.84 million |
| Other Stockholder Equity | -34.43 million | -30.91 million | N/A | -19.56 million | -25.49 million |
| Property, Plant & Equipment | 270.29 million | 264.26 million | N/A | 238 million | 224.51 million |
| Total Current Assets | 427.19 million | N/A | 464.62 million | 469.53 million | 410.1 million |
| Long Term Investments | N/A | N/A | N/A | 41.25 million | 30.38 million |
| Net Tangible Assets | 119.5 million | 117.76 million | N/A | 102.89 million | 99.15 million |
| Short Term Investments | N/A | N/A | 35.86 million | 44.63 million | 33.57 million |
| Long Term Debt | N/A | N/A | 324.44 million | 324.89 million | 316.29 million |
| Inventory | 11.69 million | N/A | 10.86 million | 10.75 million | 12.2 million |
| Accounts Payable | 44.14 million | N/A | 41.79 million | 31.32 million | 27.97 million |
Evotec SE (EVOTF) Chart:
Evotec SE (EVOTF) News:
Below you will find a list of latest news for Evotec SE (EVOTF) from major news sources. You can filter the results to only show news from a specific source.
No recent news available
Evotec SE (EVOTF) Options:
A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.
| Expiration Date | Strike | Last Price | Type | Volume | Open Interest | Implied Volatility | In The Money | Change | Change Percent |
|---|
Evotec SE (EVOTF) SEC Filings:
An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.
| Date | Form Type | Form Name | Link |
|---|